Objectives: To describe the epidemiology, clinical features and treatment of dengue fever and dengue shock syndrome.
Introduction
Dengue is a mosquito-borne disease caused by one of the four serotypes of dengue viruses. It is characterized by fever and mild constitutional symptoms to hemorrhagic manifestations and shock, or dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Dengue fever is classically a self-limiting, nonspecific illness characterized by fever, headache, myalgia, and constitutional symptoms. DHF is a more serious clinical entity. It emerged among children in Southeast Asia during the 1950s and has since become a major public health problem worldwide and a significant cause of pediatric morbidity and mortality. The affected children need very careful monitoring. The fluid therapy is challenging and needs modification frequently. Respiratory distress due to extensive pleural effusions, myocardial dysfunction, extensive bleeding and multiple organ failure, including acute respiratory distress syndrome, acute liver failure, and acute renal failure are other potentially life-threatening complications that may need attention in the pediatric intensive care unit (PICU).
Global burden
The global prevalence of dengue has grown dramatically in recent decades. The disease is now endemic in 112 countries of Africa, the Americas, the Eastern Mediterranean, Southeast Asia and the Western Pacific. WHO estimates that 40% of the world's population, about 2.5 billion people living in tropical and subtropical areas are at risk. Every year about 50-100 million cases of dengue infection, 500,000 cases of DHF and at least 12,000 deaths occur worldwide; ninety percent of these deaths occur in children less than 15 years of age. 1, 2 More than 160,000
cases of dengue and dengue hemorrhagic fever have been supportive therapy, such rates can be reduced to less than 1%.
Dengue viruses
Dengue is caused by 40-to 50-mm single-stranded RNA viruses belonging to the Flavivirus group. They are spherical and have a lipid envelope derived from host cell membranes.
Four species, known as serotypes, have been described,:
DEN-1, DEN-2, DEN-3, and DEN-4. The viral genome encodes three structural proteins (capsid, C, membrane protein, M, and envelope glycoprotein, E) and seven non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5 15 There are, however, difficulties in using these definitions as they may underestimate disease severity. The use of a higher cutoff point for platelet count (< 150,000 per μL) and higher hematocrit levels for plasma leakage (either hematocrit level of 50% or over or hemoconcentration of 10% or over) has been suggested.
Caution is needed as new case definition may affect estimation of dengue severity.
In mild to moderate cases, fever subsides with profuse sweating. Mild changes in pulse rate and blood pressure may be noticed with cold extremities and skin congestion. Patients recover spontaneously or after fluid and electrolyte therapy.
In severe cases, sudden deterioration may occur after a few days, with progression to DSS. into this category may be seen in significant numbers in epidemics. 20 Since hypovolemia and hypotension do not occur in this group of children, fluid requirement is lesser than in DHF. 21 It is therefore important to distinguish these children from those with classical DHF.
Convalescence in DHF is usually short and uneventful.
The return of appetite is a good indicator of recovery from shock. Bradycardia is also seen in this period. If present, a confluent petechial rash with erythema and islands of pallor 
Unusual manifestations: complications
Unusual manifestations of DHF/DSS include hepatitis, encephalitis and glomerulonephritis. 22 Myocardial dysfunction has also been reported. 
Management
WHO has issued a document focusing on the guidelines for treatment of dengue fever and DHF/DSS. 31 These guidelines are easy to follow and can be used in any hospital until the patient is admitted to an intensive care unit (ICU).
Indications for admission to hospital are shown in Table 1 and the steps to the management of a patient in febrile phase are shown in Table 2 .
The treatment of dengue fever in the febrile phase is symptomatic (Table 2) . Fever is treated with paracetamol.
Salicylates and other nonsteroidal anti-inflammatory drugs should be avoided as these may predispose a child to mucosal bleeding. In an epidemic setting, all patients with dengue fever need regular monitoring by a primary care physician for early detection of DHF. The health care provider should monitor the patient for clinical features of DHF/DSS along with hematocrit and platelet counts, if possible. Any patient Children with rising hematocrit levels and thrombocytopenia without clinical symptoms should also be hospitalized.
Children should be encouraged to improve their oral fluid intake. As there are no specific antiviral medications for dengue infections, supportive and aggressive fluid therapy are the cornerstone of management. Early recognition of these conditions is crucial for the reduction of case fatality rates.
The most important element of treatment in a critically ill patient or in a patient with DSS is providing intensive care with close monitoring of blood pressure, hematocrit levels, platelet count, urinary output, hemorrhagic manifestations, and level of consciousness (Table 3) . With adequate and appropriate fluid replacement, DSS is rapidly reversible. In a retrospective study of 858 patients with dengue fever/DHF admitted to a hospital in India, 109 cases with severe forms of the disease required PICU admission, The commonest indication for PICU admission was persistent shock (39 patients) followed by requirement for positive pressure In young infants without shock-N/2 saline in 5% dextrose; colloid solutions in patients who already have volume overload, i.e., massive pleural effusion
Fluid replacement rate -minimum necessary to maintain effective circulatory volume, excess amount will leak into the pleural and peritoneal spaces
Initial rate of administration DSS grade III -10 mL/kg/hour for 1-2 hours
Grade IV -Free flow or 20 mL/kg/dose IV bolus until BP can be measured (usually within 5-15 minutes), then reduce the rate to 10 mL/kg/hour for 1-2 hours Non-shock patients: normal maintenance or + 5% deficit and then reduce the rate to minimum after 2-4 hours, if possible. Body weight < 15 kg: 4-7 mL/kg/hour. Body weight 15-40 kg: 3-5 mL/kg/hour Colloids: The initial rate is 10 mL/kg/hour; this will reduce Hct by about 10 percentage points e.g. from 53 to 43%. After that, reduce to 5, then to 3 mL/kg/hour Increase or decrease the rate of IV fluid depending on: clinical signs of shock, hematocrit level, urine output
In case of no response to IV fluids: consider and correct
Massive plasma leakage
Concealed internal bleeding -decrease in Hct
Hypoglycemia -Blood sugar < 60 mg% Hyponatremia, hypocalcemia -electrolytes Acidosis -indicates metabolic acidosis in blood gas analysis Duration of IV fluid infusion: between 24-48 hours as plasma loss may continue for 24-48 hours. It should be discontinued when the hematocrit level falls to approximately 40%, with stable vital signs. A good urine flow indicates sufficient circulating volume. Reabsorption of extravasated plasma occurs 48 hours after the termination of shock (manifested by a further drop in hematocrit levels after intravenous fluid administration has been stopped), and hypervolemia, pulmonary edema or heart failure may occur if more fluid is given. It is extremely important that a drop in hematocrit levels at this later stage is not interpreted as a sign of internal bleeding.Strong pulse and blood pressure and adequate diuresis are good signs at this stage. The return of the patient's appetite is also a sign of recovery.
(cont.)
Dengue and dengue hemorrhagic fever -Singhi S et al. there were no differences in treatment response in all other measures. 35 Significantly more recipients of dextran than of starch had adverse reactions. Bleeding manifestations, coagulation derangements, and severity of fluid overload were similar for all fluid-treatment groups. In this study, the authors concluded that initial resuscitation with Ringer's lactate is acceptable for children with moderately severe dengue shock syndrome. 35 Hydroxyethyl starch at 6% may be preferred in children with severe shock; the use of dextran is associated with various adverse reactions.
WHO guidelines are useful in that they offer an algorithmic approach to fluid resuscitation in DHF and DSS.
However, the usefulness of these guidelines is limited beyond performance, which may be easily detected by echocardiography. 23, 37 Low platelet count may not be predictive of bleeding. 38, 39 Platelets or blood should not be transfused based upon platelet count alone. 36 In children with severe thrombocytopenia in absence of significant bleeding, platelet infusion does not alter the outcome. 40 Infusion of fresh frozen plasma and platelet concentrates may be beneficial in patients with disseminated intravascular coagulation.
Treatment with methylprednisolone did not show any benefit DHF = dengue hemorrhagic fever; IV = intravenous; NS = normal saline solution; RL = Ringer's lactate solution. in a double blind placebo-controlled trial in patients with DSS. 41 The treatment of complications is outlined in Table 4 . causes of death in a recent series. 32 The case fatality rate is high with shortage of experienced medical teams.
Prognosis

Prevention and control
At present, no specific drug or vaccine is available against the dengue virus. The control is primarily dependent on vector control. 
Future issues
Dengue is an important public health problem that causes great expenses because of temporary absenteeism from work, and undermines regional and national economic development. 43 
